Project Grant R01HL173837
Award Date
5/20/25
Completion Date
2/28/29
Dollars Obligated
$816K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The University of Texas Southwestern Medical Center was awarded a $815,229 Project Grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct proteomic profiling research on cardiac dysfunction and arrhythmia in Black Americans. The project aims to use proteomics and genomics to identify biological pathways responsible for the development of heart failure and atrial fibrillation, as well as mechanisms linking social determinants of health...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth). The 7-year award, running from March 1, 2025 to December 31, 2031, will support UTHealth's "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The program encompasses three...
This $2,454,955 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research by the Beckman Research Institute of the City of Hope to investigate the integrative role of the RPS6KB1 protein in the pathological cardiac remodeling process that leads to heart failure. The research aims to elucidate the mechanisms by which RPS6KB1 regulates adaptive cardiac hypertrophy,...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $748,647 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to William Marsh Rice University. The grant, effective September 17, 2024 through August 31, 2025, will fund a longitudinal, mixed-methods study to characterize how food insecurity and trauma concurrently and prospectively influence cardiovascular disease risk and psychological well-being among...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $732,779 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arizona to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The project aims to determine how cardiac-specific SGK1 influences heart function, metabolism, and inter-organ communication in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $100,480 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Texas Southwestern Medical Center. The grant, titled "RBPMS, A NOVEL RNA SPLICING REGULATOR OF CARDIAC FUNCTION AND DISEASE", will support research to characterize how the RNA-binding protein RBPMS regulates cardiomyocyte contraction and cardiac function through modulating alternative RNA splicing. The project...
This $817,208 Project Grant was awarded on January 3, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at the Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project will leverage high-throughput assays, including cell painting and Perturb-seq, to link genes associated with HF risk through genome-wide association...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $748,829 to Texas A&M University System Health Science Center (TAMU HSC) to investigate the metabolic resuscitation system and its connection to the pathogenesis of heart failure. The overarching objective is to determine how a compromised metabolic resuscitation system contributes to the progression of heart failure and explore this...
This $154,568 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the metabolic and cardiac consequences of lipoic acid deficiency. The goal is to use a mouse model of cardiac-specific lipoylation deficiency to gain insights into the mechanisms by which impaired metabolic flexibility leads to cardiac dysfunction, a hallmark of heart failure. The research team at...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $655,636 to the Texas Heart Institute (THI) to investigate cardiac fibroblast mechanisms in single ventricle disease (CVD) and heart failure. The key objectives are to gain insights into CVD pathology and uncover new therapeutic targets, with the long-term goal of promoting productive heart repair in failing CVD hearts. The research...